Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 40 countries for the treatment of PNH, and in the United States for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.
The Research Associate III contributes to Discovery Research through the design and execution, and documentation of experiments at the lab bench
The RA III actively contributes to the protein sciences division of the discovery research group by performing and developing binding assays (such as ELISA, FACS), as well as routine protein purification and characterization in collaboration with group members.
With guidance of Research Scientist, the RA III will develop both pharmacokinetic and pharmacodynamic assays for new drug candidates, using conventional plate-based and cell-based techniques.
The RA is expected to independently plan, design, execute and troubleshoot experiments
The RA III is expected to participate in methods and tech transfer of assays interdepartmentally.
The RA III will be responsible for detailed record keeping using established electronic notebook procedures, as well as keeping internal databases updated.
The Research Associate III will report research progress through individual and group meetings, presentations and written documents both internally and externally.
The RA III does not have managerial responsibilities.
The Research Associate III should have a minimum of 5-8 years of relevant experience and exemplify the following attributes:
The candidate should demonstrate a track record of organizational skill and exquisite attention to detail.
The candidate should be able to plan, design, execute and troubleshoot projects with minimal supervision
Good oral and written communication skills are essential.
The individual in this position will have a working knowledge of the research laboratory environment and be familiar with all basic and some complex laboratory equipment / instrumentation
The RA should have technical expertise in the following areas: ELISA, W Blot, IP, electrophoresis, protein purification/expression, binding assays, aseptic technique/cell culture. Some familiarity with flow cytometry, standard molecular biology processes (cloning, expression), Octet kinetics applications, and enzyme assays is desirable.
Software experience with Unicorn, LaserGene, MS office GraphPad Prism and similar applications is also desirable.
B.Sc. or equivalent degree in Pharmacology, Cell or Molecular Biology, Chemistry, Biochemistry, or other biomedical science with 8 + years of relevant laboratory experience, or an M.Sc. or equivalent degree and 3+ years of experience.
As a leading employer in our industry, Alexion is proud to offer a highly competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, 401(k) with company match, tuition reimbursement, relocation assistance and much more. To learn more about Alexion, please visit www.alexionpharma.com or download our App for iPhones and Blackberries.
Alexion is an Equal Opportunity /Affirmative Action employer.
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic...